A clinical study has shown that patients who develop CNV have significantly lower expression levels in PRs of the soluble form of the VEGF receptor (sFLT-1) [73,74], attributing a potential role to PRs in maintaining VEGF homeostasis in AMD, and contributing to neovascular pathologies. The gene discussed is VEGFA; the disease is age-related macular degeneration.